scholarly journals Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss

2006 ◽  
Vol 15 (3) ◽  
pp. 101-107 ◽  
Author(s):  
Takuo Kubota ◽  
Noriyuki Namba ◽  
Shunji Kurotobi ◽  
Shigetoyo Kogaki ◽  
Haruhiko Hirai ◽  
...  
Keyword(s):  
Bone Loss ◽  
Beneficial Effect ◽  
Chronic Administration ◽  
Urinary Calcium ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate ◽  
Calcium Loss

Thyroparathyroidectomy exaggerates calciuric action of ammonium chloride in rats

1984 ◽  
Vol 246 (1) ◽  
pp. F54-F58 ◽  
Author(s):  
A. Goulding ◽  
D. R. Campbell
Keyword(s):  
Bone Resorption ◽  
Ammonium Chloride ◽  
Chronic Administration ◽  
Urinary Calcium ◽  
Urinary Hydroxyproline ◽  
Renal Tubular Reabsorption ◽  
Renal Tubular ◽  
Hydroxyproline Excretion ◽  
Calcium Loss ◽  
Intact Rats

The effects of chronic ammonium chloride (NH4Cl) administration on urinary calcium, urinary hydroxyproline, and calcium and phosphate balances were studied in intact and thyroparathyroidectomized (TPTX) rats. NH4Cl (2 g/100 g diet) was administered for 16 days to growing rats consuming a low calcium (0.1% Ca) diet. NH4Cl increased urinary calcium and hydroxyproline. NH4Cl caused greater urinary calcium loss in TPTX than in intact rats, but hydroxyproline excretion in these groups was similar. Compensatory increases in net alimentary absorption of calcium and phosphate occurred in intact but not in TPTX rats. Urinary cAMP was depressed by thyroparathyroidectomy but was unaffected by NH4Cl. It is concluded that NH4Cl depresses renal tubular reabsorption of calcium and increases bone resorption in the presence and absence of the thyroid and parathyroid glands. However, our results suggest that parathyroid hormone plays an important calcium-sparing role, while calcitonin may act to limit the rate of bone resorption, in intact rats during chronic administration of NH4Cl.

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy

2020 ◽  
Vol 30 (7) ◽  
pp. 599-610
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Irina Rybalsky ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Glucocorticoid Therapy ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate

scholarly journals Effect of high vegetable protein diets on urinary calcium loss in middle-aged men and women

2003 ◽  
Vol 57 (2) ◽  
pp. 376-382 ◽  
Author(s):  
D J A Jenkins ◽  
C W C Kendall ◽  
E Vidgen ◽  
L S A Augustin ◽  
T Parker ◽  
...  
Keyword(s):  
Vegetable Protein ◽  
Urinary Calcium ◽  
Middle Aged ◽  
Men And Women ◽  
Protein Diets ◽  
Calcium Loss

Republished: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis

2021 ◽  
pp. dtb-2021-235083rep
Author(s):  
Louise Wulff Bagger ◽  
Per Kim Dyhr Hansen ◽  
Peter Schwarz ◽  
Barbara Rubek Nielsen
Keyword(s):  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate

Health-related quality of life in osteoporosis clinical trials urinary calcium loss

1993 ◽  
Vol 53 (2) ◽  
pp. 75-77 ◽  
Author(s):  
Gail A. Greendale ◽  
Stuart L. Silverman ◽  
Ron D. Hays ◽  
Cyrus Cooper ◽  
Timothy Spector ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Urinary Calcium ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Calcium Loss

scholarly journals Annual alveolar bone loss in older adults taking oral bisphosphonate: a retrospective cohort study

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mohammad Helmi ◽  
Sara AlOsaimy ◽  
J. Max Goodson ◽  
Hatice Hasturk ◽  
Zuhair S. Natto
Keyword(s):  
Older Adults ◽  
Cohort Study ◽  
Bone Loss ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Alveolar Bone ◽  
Periodontal Diseases ◽  
Alveolar Bone Loss ◽  
Oral Bisphosphonate ◽  
Associated Risk Factors

Abstract Background Although several studies assessed the effect of bisphosphonate (BIS) administration on alveolar bone loss, this relationship has not been fully investigated using longitudinal analysis. The aim of the this article is to predict annual alveolar bone loss in a subpopulation of older adults patients who were taking oral bisphosphonate (BIS), adjusting for systemic diseases and associated risk factors. Methods This is a retrospective cohort study. We identified all subjects who reported receiving oral bisphosphonate from 2008 to 2015 (N = 30) using the electronic health records of each patient to identify suitable radiographs for analysis. For the longitudinal data analysis, 26 subjects were eligible for inclusion, having at least two exposures of the complete mouth set or repeated bitewing radiographs at least a one-year interval; they were then matched on age and sex to another 26 patients who did not report receiving bisphosphonate at any point of their life. Results Mild periodontitis was higher in the BIS group compared to the no BIS group; however, moderate periodontitis was higher in the no BIS group. For those who did not take oral BIS, change over time was not significant after the two-year period. However, the BIS group had experienced 0.088 mm more bone loss compared to the no BIS group (95% CI: 0.001, 0.176. P-value = 0.048), adjusting for all other variables included in the model. Conclusion The group that reported receiving oral bisphosphonates showed no improvement in maintaining alveolar bone level, and the use of oral BIS may not be effective in reducing annual alveolar bone loss; however, emerging evidence is promising for the use of bisphosphonate as an adjunctive local delivery medication for the management of periodontal diseases.

Dietary determinants of post-menopausal bone loss at the lumbar spine: a possible beneficial effect of iron

2006 ◽  
Vol 17 (8) ◽  
pp. 1165-1173 ◽  
Author(s):  
R. Abraham ◽  
J. Walton ◽  
L. Russell ◽  
R. Wolman ◽  
B. Wardley-Smith ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Loss ◽  
Beneficial Effect ◽  
Post Menopausal

scholarly journals Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy

2008 ◽  
Vol 26 (27) ◽  
pp. 4426-4434 ◽  
Author(s):  
Susan L. Greenspan ◽  
Joel B. Nelson ◽  
Donald L. Trump ◽  
Julie M. Wagner ◽  
Megan E. Miller ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Density ◽  
Bone Loss ◽  
Bone Turnover ◽  
Androgen Deprivation Therapy ◽  
Bisphosphonate Therapy ◽  
Androgen Deprivation ◽  
Mineral Density ◽  
Skeletal Health ◽  
Oral Bisphosphonate

Purpose Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures. Our objective was to examine changes in bone density and turnover with sustained, discontinued, or delayed oral bisphosphonate therapy in men receiving ADT. Patients and Methods A total of 112 men with nonmetastatic prostate cancer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year 2 for those who initially received active therapy. Outcomes included bone mineral density and bone turnover markers. Results Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continue had additional bone density gains at the spine (mean, 2.3% ± 0.7) and hip (mean, 1.3% ± 0.5%; both P < .01); those randomly assigned to placebo in year 2 maintained density at the spine and hip but lost (mean, −1.9% ± 0.6%; P < .01) at the forearm. Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone mass at the spine and hip, but experienced less of an increase compared with those who initiated alendronate at baseline. Men receiving alendronate for 2 years experienced a mean 6.7% (± 1.2%) increase at the spine and a 3.2% (± 1.5%) at the hip (both P < .05). Bone turnover remained suppressed. Conclusion Among men with nonmetastatic prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover. A second year of alendronate provides additional skeletal benefit, whereas discontinuation results in bone loss and increased bone turnover. Delay in bisphosphonate therapy appears detrimental to bone health.

Sign in / Sign up

Export Citation Format

Share Document